In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy CMG1A46 from Chimagen Biosciences, a privately-held biotechnology company based in China. Per the terms of the deal, GSK will pay Chimagen $300 million upfront to develop and commercialize CMG1A46 with a focus on autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Chimagen may also be eligible for an additional $550 million following success-based development and commercial milestones.
CMG1A46 is a dual CD19/CD20 targeted T cell-engager directed at deep B cell depletion. In preclinical studies, CMG1A46 has shown rapid, deep B cell depletion both in the bloodstream and in tissues. The drug is currently in a phase 1 clinical trial for leukemia and lymphoma (types of blood cancer) in the U.S. and China. GSK has plans to begin a phase 1 trial for lupus in 2025.
Continue to follow the Lupus Foundation of America for updates on CMG1A46. Learn more about medications used to treat lupus.
This post was originally published on this site